CJC-1295 without DAC (Modified GRF 1-29) – Research Peptide

CJC-1295 without DAC (Modified GRF 1-29) – Research Peptide
Class: Growth Hormone Releasing Hormone (GHRH) analog  
Form: Lyophilized powder
Purity: ≥ 99% (HPLC verified)
Storage (dry): Room temperature, away from light
Storage (reconstituted): Refrigerate 2–8°C
Solvent compatibility: Bacteriostatic Water (preferred)  
CJC-1295 without DAC (Drug Affinity Complex), also known as Modified GRF 1-29, is a synthetic analog of the naturally occurring growth hormone-releasing hormone. By modifying the first 29 amino acids of GHRH, researchers have developed a more stable compound for laboratory study. It is widely utilized in research settings to investigate pulsatile growth hormone secretion and its subsequent effects on cellular growth and metabolic signaling.  
Key Research Focus Areas
Pulsatile GH Secretion: Investigation of the peptide's ability to stimulate the anterior pituitary to release growth hormone in natural, episodic pulses.  
Protein Synthesis & Muscle Hypertrophy: Study of the downstream effects on IGF-1 levels and their role in nitrogen retention and muscle tissue modeling.
Lipolysis & Metabolic Rate: Analysis of the peptide’s influence on adipose tissue breakdown and systemic lipid metabolism in research models.
Cellular Repair & Recovery: Researching the impact of enhanced GH signaling on the recovery of stressed or damaged musculoskeletal tissues.
Sleep Quality & Circadian Rhythm: Evaluation of the correlation between GHRH analogs and the regulation of deep-wave sleep cycles in pre-clinical settings.
Format Options







5 mg lyophilized powder
Optional BAC solvent available separately
Important Notice
All products are sold for laboratory research use only. Not for human consumption, injection, or diagnostic use.